Compare DexCom, Inc. (DXCM) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Stanley Black & Decker, Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Stanley Black & Decker, Inc. trades at $88.57 (market cap $13.47B). The key difference: DexCom, Inc. is far larger — about 2.4× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| DXCM | SWK | |
|---|---|---|
Market Cap | $31.86B | $13.47B |
Volume | 3,607,070 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $92.34 | $104.00 |
52-Week Low | $54.84 | $62.12 |
Typical Hold Time | 62 Days | 62 Days |
Enterprise Value | $31.32B | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Stanley Black & Decker (SWK) trades at $89.17, up 0.97% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin rising to 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89, while analyst consensus leans neutral with 43% buy ratings and $93 price target.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness and competitive pressures. The stock offers value characteristics with dividend stability but faces execution risks in achieving projected earnings growth. Near-term direction will depend on Q3 2026 results due November 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
